| 潘耀耀,马晓楠,陈 呈,陈日月,李 炅.硫酸羟氯喹口服辅助治疗糜烂型口腔扁平苔癣的效果及对AT-Ⅲ、ZAG的影响[J].,2021,(22):4372-4376 |
| 硫酸羟氯喹口服辅助治疗糜烂型口腔扁平苔癣的效果及对AT-Ⅲ、ZAG的影响 |
| Effect of Oral Adjuvant Treatment of Erosive Oral Lichen Planus with Hydroxychloroquine Sulfate and Its Effect on AT-Ⅲ and ZAG |
| 投稿时间：2021-04-28 修订日期：2021-05-24 |
| DOI：10.13241/j.cnki.pmb.2021.22.036 |
| 中文关键词: 硫酸羟氯喹 辅助治疗 糜烂型口腔扁平苔癣 人抗凝血酶Ⅲ 锌α2糖蛋白 |
| 英文关键词: Hydroxychloroquine sulfate Adjuvant therapy Erosive oral lichen planus Human antithrombin Ⅲ Zinc α2 glycoprotein |
| 基金项目:安徽省自然科学基金项目（150885SQH222） |
|
| 摘要点击次数: 706 |
| 全文下载次数: 412 |
| 中文摘要: |
| 摘要 目的：探讨硫酸羟氯喹口服辅助治疗糜烂型口腔扁平苔癣的效果及对人抗凝血酶Ⅲ（AT-Ⅲ）、锌α2糖蛋白（ZAG）的影响。方法：选择2018年12月-2021年1月在我院接受治疗的115例糜烂型口腔扁平苔癣患者，采用随机数表法分为治疗组（n=58）和对照组（n=57）。对照组给复方倍他米松治疗，治疗组在对照组的基础上联合硫酸羟氯喹口服治疗。比较两组临床疗效、AT-Ⅲ、ZAG、白细胞介素4（IL-4）、白细胞介素17（IL-17）、干扰素γ（IFN-γ）、糜烂面积、疼痛评分水平变化情况及不良反应发生情况。结果：治疗后，两组总有效率比较差异显著（P<0.05）；治疗前，治疗组和对照组血清AT-Ⅲ、ZAG比较无显著差异；治疗后，治疗组和对照组血清AT-Ⅲ、ZAG均随着时间的推移而降低，且治疗组均低于对照组，差异显著（P<0.05）；治疗前，治疗组和对照组实验室指标水平比较无显著差异；治疗后，治疗组和对照组IL-4、IL-17均随着时间的推移而降低，且治疗组均低于对照组，IFN-γ均随着时间的推移而升高，且治疗组均高于对照组，差异显著（P<0.05）；治疗前，治疗组和对照组糜烂面积、疼痛评分比较无显著差异；治疗后，治疗组和对照组糜烂面积、疼痛评分均随着时间的推移而降低，且治疗组均低于对照组，差异显著（P<0.05）；两组不良反应总发生率为3.45%、8.77%，无显著差异（P>0.05）。结论：在糜烂型口腔扁平苔癣中应用硫酸羟氯喹口服辅助治疗疗效显著，可有效改善患者AT-Ⅲ、ZAG水平。 |
| 英文摘要: |
| ABSTRACT Objective: To study Effect of oral adjuvant treatment of erosive oral lichen planus with hydroxychloroquine sulfate and its effect on Human antithrombin Ⅲ (at-Al), zinc α2 glycoprotein (Zag). Methods: 115 patients with eroded oral lichen planus treated in our hospital from December 2018 to January 2021 were selected and divided into treatment group (n=58) and control group (n=57) by random number table method. The control group was treated with compound betamethasone, and the treatment group was combined with oral treatment of hydroxychloroquine sulfate on the basis of the control group. The clinical efficacy, AT-Ⅲ, Zag, interleukin-4 (IL-4), interleukin-17 (IL-17), interferon γ (IFN-γ), erosion area, pain score changes and the incidence of adverse reactions were compared between the two groups. Results: After treatment, the total effective rate between the two groups was significantly different (P<0.05). Before treatment, there were no significant differences between the treatment group and the control group in serum AT-Ⅲ and Zag. After treatment, serum AT-Ⅲ and Zag in treatment group and control group decreased with the passage of time, and treatment group was lower than control group, the differences were significant (P<0.05). Before treatment, there was no significant difference in the laboratory index levels between the treatment group and the control group. After treatment, IL-4 and IL-17 in treatment group and control group decreased with the passage of time, and the treatment group was lower than the control group, IFN-γ increased with the passage of time, and the treatment group was higher than the control group, the difference was significant(P<0.05); Before treatment, there were no significant differences in erosion area and pain score between the treatment group and the control group. After treatment, erosion area and pain score of both treatment group and control group decreased with the passage of time, and the treatment group was lower than the control group, the differences were significant(P<0.05). The total incidence of adverse reactions between the two groups was 3.45% and 8.77%, with no significant difference(P>0.05). Conclusion: Oral adjuvant treatment of erosive oral lichen planus with hydroxychloroquine sulfate is effective, which can effectively improve the levels of AT-Ⅲ and Zag in patients. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
